Distribution of pre- and mid-pandemic transfusions by blood types

Abstract

Introduction: COVID-19 disease spread rapidly worldwide, causing a pandemic. In this study, we aimed to explore the distribution of blood products in our blood center before and during the pandemic by blood type. Material and Method: In this study, we retrospectively analyzed 4,271 blood products (1,290 patients) transfused before and during the pandemic through the medical records of Kastamonu Training and Research Hospital Blood Transfusion Center. Moreover, we investigated the associations between transfusions and age, sex, blood type, and COVID-19 infection. Results: The findings revealed that the majority of the patients receiving transfusions both before and during the pandemic were A Rh (+) (41.4%). Besides, the rates of those with O Rh (+) were 28.8% and 28.7% during the pandemic. In addition, 37 products (28 erythrocyte suspensions, 7 fresh frozen plasma, 2 pooled platelet suspensions) were transfused on 17 patients with confirmed COVID-19. Conclusion: Transfusions have an important place in the treatment of critically ill patients. The blood type A Rh (+) was previously shown to be associated with an increased risk of COVID-19 infection. In this study, although we realized that products of blood type A were mostly used in general transfusions, transfusions in the pandemic were performed predominantly with blood products of infected patients with blood type O. The modern world is more likely to encounter further pandemics in the future. We think that each region should evaluate its own centers.

Keywords

• Transfusion
• Covid 19
• ABO Blood Group
• Rh
• Blood Transfusion Center

References

1. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395: 507–13.
2. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. HC. JAMA 2020; 324: 782-93.
3. Mollison PL, Engelfriet P. Blood transfusion. Semin Hematol 1999; 36: 48-58.
4. Kasanga M, Mudenda S, Gondwe T, Chileshe M, Solochi B, Wu J. Impact of COVID-19 on blood donation and transfusion services at Lusaka provincial blood transfusion centre, Zambia. Pan Afr Med J 2020; 35: 74.
5. Mohammadi S, Yazdi SMT, Eshghi P, Norooznezhad AH. Coronavirus disease 2019 (COVID-19) and decrease in blood donation: experience of Iranian Blood Transfusion Organization (IBTO). Vox Sang 2020; 115: 595-6.
6. Hof L, Choorapoikayil S, Meybohm P, Zacharowski K. Patient blood management in intensive care patients. Curr Opin Crit Care 2021; 27: 709-16.
7. Rana R, Ranjan V, Kumar N. Association of ABO and Rh blood group in susceptibility, severity, and mortality of coronavirus disease 2019: a hospital-based study from Delhi, India. Front Cell Infect Microbiol 2021: 2; 11: 767771.
8. Koçtekin B. Antalya Eğitim ve Araştırma Hastanesi Transfüzyon Merkezi’ne başvuran donörlerde ABO ve Rhesus (Rh) kan grupları dağılımının araştırılması. Mersin Üniv Saglık Bilim Derg 2020; 13: 395-403.

9. Maatoghi JT, Paridar M, Shoushtari MM, et al. Distribution of ABO blood groups and rhesus factor in a large scale study of different cities and ethnicities in Khuzestan province, Iran. Egypt J Med Human Gen 2016; 17: 105–9.
10. Franchini M, Liumbruno GM. ABO blood group: old dogma, new perspectives. Clin Chem Lab Med 2013; 51: 1545-53.
11. Yalaoui S, Fakhfakh R, Tritar F, et al. ABO blood groups and risk of COVID-19. Tunis Med 2020; 98: 888-91.
12. Boudin L, Janvier F, Bylicki O, Dutasta F. ABO blood groups are not associated with the risk of acquiring SARS-CoV-2 infection in young adults. Haematologica 2020; 105: 2841–3.
13. Stanworth SJ, New HV, Apelseth TO, et al. Effects of the COVID-19 pandemic on supply and use of blood for transfusion. Lancet Haematol 2020; 7: 756-64.
14. Pál S, Réger B, Kiss T. et al. Effect of SARS-CoV-2 pandemic on blood product usage at the University of Pécs. Orv Hetil 2021; 162: 1717-23.
15. Wu BB, Gu DZ, Yu JN, Yang J, Wang-Qin S. Association between ABO blood groups and COVID-19 infection, severity and demise: a systematic review and meta-analysis. Infect Genet Evol 2020; 84: 104485.
16. Pourali F, Afshari M, Alizadeh-Navaei R, Javidnia J, Moosazadeh M, Hessami A. Relationship between blood group and risk of infection and death in COVID-19: a live meta-analysis. New Microbes New Infect 2020; 37: 100743.
17. Li J, Wang X, Chen J, Cai Y, Deng A, Yang M Association between ABO blood groups and risk of SARS-CoV-2 pneumonia. Br J Haematol 2020; 190: 24-7.
18. Brown BL, McCullough J. Treatment for emerging viruses: convalescent plasma and COVID-19.Transfus Apher Sci 2020; 59: 102790.
19. Cesilia C, Ridar E, Suryawan N, Nataprawira HM. Convalescent plasma therapy in obese severe COVID-19 adolescents: Two cases report. Ann Med Surg (Lond) 2021; 72: 103084.
20. Farrugia A, Robert P. Plasma protein therapies: current and future perspectives. Best Pract Res Clin Haematol 2006; 19: 243-58.
21. Lippi G, Plebani M , Henry BM . Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin Chim Acta 2020; 506: 145-8.
22. Marcos SZ, Antelo ML , Galbete A, Etayo M, Ongay E , Garcia-Erce AJ. Infection and thrombosis associated with COVID-19: Possible role of the ABO blood group. Med Clin (Barc) 2020; 155: 340-3.